Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression - ATAI Life Sciences (NASDAQ:ATAI)
Source: benzinga.com
Feilding Mellen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Feilding Mellen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Feilding Mellen Today - Breaking & Trending Today
Beckley Psytech Ltd: Beckley Psytech initiates Phase IIa study of 5-MeO-DMT candidate BPL-003 for Alcohol Use Disorder
Open-label study will investigate the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD). BPL-003 is Beckley Psytech's patent-protected
Source: finanznachrichten.de
Initiative aims to bring Psychedelic Medicines to Clinical Stage
Under an R&D partnership Beckley Psytech, dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, will jointly fund continuing development of Lophora ApS’ pipeline of proprietary NCEs for treatment-resistant depression, and other potential indications such as anxiety, post-traumatic stress disorder and substance abuse. Click to read more...
Source: labmate-online.com
Beckley Psytech Announces Partnership With Empatica in Latest Step of Digital Strategy, Designed to Deliver Personalised Patient Care
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaboration and strengthening of relationship with Lophora
Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaboration and strengthening of relationship with Lophora ApS Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckle...
Source: pharmiweb.com